6/29/23, 1:44 AM PROGRESS Pathway Feedback Search Clinical Topics Home Studies PROGRESS PROGRESS Disease Disease Acute ischemic stroke Transient ischemic attack Trial question What is the role of perindopril-based BP lowering regimen in patients with a history of stroke or TIA? Study design Multi-center Double blinded RCT Population Characteristics of study participants 30.0% female N = 6105 70.0% male 6105 patients (1852 female, 4253 male) Inclusion criteria: patients with a history of stroke or TIA Key exclusion criteria: definite indication or contraindication for treatment with ACEIs; < 2 weeks of clinical stability after the most recent vascular event Interventions N=3051 active treatment (a flexible regimen based on perindopril 4 mg daily, with the addition of indapamide at the discretion of treating physicians) N=3054 placebo (matching perindopril and indapamide placebo) Primary outcome Stroke https://web.pathway.md/studies/recg5cWTlX6NGcJ9f 1/2 6/29/23, 1:45 AM PROGRESS Pathway 14.0 % 14 10.5 % 10 7.0 % Significant decrease 3.5 % NNT = 25 0.0 % Active treatment Placebo Significant decrease in stroke (10% vs. 14%; RR 0.72, 95% CI 0.62 to 0.83) Secondary outcomes Borderline significant increase in composite outcome of nonfatal stroke, nonfatal myocardial infarction, or death from a vascular cause (15% vs. 20%; RR 26, 95% CI 16 to 34) No significant difference in death from all causes (10% vs. 10.4%; RR 0.96, 96% CI 0.82 to 1.12) Borderline significant decrease in hospital admissions (41% vs. 44%; RR 0.91, 95% CI 0.85 to 0.99) Conclusion In patients with a history of stroke or TIA, active treatment was superior to placebo with respect to stroke. Reference PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001 Sep 29;358(9287):1033-41. Open reference URL https://web.pathway.md/studies/recg5cWTlX6NGcJ9f 2/2